(NASDAQ: VCEL) Vericel's forecast annual revenue growth rate of 14.77% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.45%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.33%.
Vericel's revenue in 2026 is $306,303,000.On average, 10 Wall Street analysts forecast VCEL's revenue for 2026 to be $17,543,385,956, with the lowest VCEL revenue forecast at $16,691,307,899, and the highest VCEL revenue forecast at $18,275,640,537. On average, 10 Wall Street analysts forecast VCEL's revenue for 2027 to be $20,516,441,965, with the lowest VCEL revenue forecast at $19,390,408,523, and the highest VCEL revenue forecast at $21,914,894,594.
In 2028, VCEL is forecast to generate $23,758,332,698 in revenue, with the lowest revenue forecast at $21,817,602,027 and the highest revenue forecast at $26,298,180,752.